Abstracts tagged "Febuxostat"

Abstract Number: 1188 • 2013 ACR/ARHP Annual Meeting
An Assessment Of The Response Of Chronic, Occult, Synovial-Based Inflammation Of Gout To Serum Urate Lowering Therapy
John D. Carter¹, Michelle Patelli², Scott Anderson², Neelish Prakash², Robyn Aydelott², Ernesto Rodriguez², Helen E. Bateman³, Ashley G. Sterrett⁴, Joanne Valeriano-Marcet⁵ and Louis R. Ricca⁶, ¹Internal Medicine; Division of Rheumatology, University of South Florida, Tampa, FL, ²University of South Florida, Tampa, FL, ³Medicine / Rheumatology (111K), James A Haley VA Hospital USF, Tampa, FL, ⁴Internal Medicine/Rheumatology, JAHVA, Tampa, FL, ⁵Internal Medicine, University of South Florida, Tampa, FL, ⁶University of South Florida College of Medicine, St Petersburg, FL
Background/Purpose: We recently demonstrated that synovitis is present in the vast majority of patients with inter-critical gout and that the severity of this synovitis did…
Abstract Number: 2045 • 2012 ACR/ARHP Annual Meeting
Treatment Patterns and Monitoring of Serum Uric Acid Levels in a Large Cohort of Gout Patients in the United States: Is There Room for Improvement?
Yong Chen¹, Kasem S. Akhras², Michael Grabner¹, Rima H. Tawk³ and Ralph Quimbo¹, ¹HealthCore, Inc., Wilmington, DE, ²Global Outcomes Research, Takeda Pharmaceuticals International, Inc., Deerfield, IL, ³Center for pharmacoeconomic Research, University of Illinois at Chicago, Chicago, IL
Background/Purpose: Currently, there are no guidelines in the United States on monitoring serum uric acid (sUA) levels in gout and gout treatment patterns. However, there…
Abstract Number: 1905 • 2012 ACR/ARHP Annual Meeting
Increase of Thyroid Stimulating Hormone in Patients On Febuxostat Treatment
Fernando Perez-Ruiz¹ and Ana M. Herrero-Beites², ¹Servicio de Reumatologia, Hospital Universitario Cruces, Baracaldo, Spain, ²Physical Medicine Division, Hospital de Gorliz, Gorliz, Spain
Background/Purpose: to evaluate whether TSH increases during febuxostat treatment and factors that could be implicated.Methods: before starting febuxostat, patients had analysis at baseline and month…
Abstract Number: 1814 • 2012 ACR/ARHP Annual Meeting
Comparing Clinical Characteristics and Comorbidities of Gout Patients Treated with Allopurinol or Febuxostat
Michael A. Becker¹, Xiangyang Ye², Kasem S. Akhras³, Rima H. Tawk⁴, Sudhir Unni², Jason Young² and Carl V. Asche⁵, ¹Medicine, University of Chicago, Chicago, IL, ²University of Utah College of Pharmacy, Salt Lake City, UT, ³Global Outcomes Research, Takeda Pharmaceuticals International, Inc., Deerfield, IL, ⁴Center for pharmacoeconomic Research, University of Illinois at Chicago, Chicago, IL, ⁵Center for Outcomes Research, University of Illinois College of Medicine at Peoria, Peoria, IL
Background/Purpose: Gout is a common acute and potentially progressive disease affecting approximately 8 million Americans. Hyperuricemia (serum urate levels [sUA] >6.8mg/dL) is a major pathogenic…
Abstract Number: 153 • 2012 ACR/ARHP Annual Meeting
Prevention of Recurrent Calcium Stones in Subjects with Hyperuricosuria: A Randomized Controlled Trial of Febuxostat Vs Allopurinol
David S. Goldfarb¹, Patricia A. MacDonald², Lhanoo Gunawardhana³, Solomon Chefo³ and Lachy McLean⁴, ¹New York Universtiy Langone Medical Center, New York, NY, ²Takeda Pharmaceuticals USA, Inc., Deerfield, IL, ³Takeda Global Research & Development Center, Inc., Deerfield, IL, ⁴Takeda Global Research & Development Center, Inc, Deerfield, IL
Background/Purpose: About one-third of patients with recurrent calcium oxalate (CaOx) stones have hyperuricosuria as a urinary risk factor. Febuxostat (FEB), a newer xanthine oxidase inhibitor…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].